Morphic therapeutics market cap
WebGet the latest Morphic Holding Inc (MORF) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. WebRevenue for Morphic Therapeutic (MORF) Revenue in 2024 (TTM): $70.8 M According to Morphic Therapeutic's latest financial reports the company's current revenue (TTM) is …
Morphic therapeutics market cap
Did you know?
WebApr 12, 2024 · Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, … WebMar 6, 2024 · RBC Capital Markets Healthcare Conference Fireside Chat. May 18, 2024 at 1:55 PM EDT 41st Annual Cowen Health Care Conference. Mar 2, 2024 at 11:10 AM EST Morphic Financial and Operational Results 2024 Year End Conference Call. Mar 1, 2024 at 8: ... ©2024 Morphic Therapeutics, Inc.
WebApr 14, 2024 · BioXcel Therapeutics Inc. (BTAI) current stock price is $19.14. During the last trading session, the stock soared, reaching $19.71 after opening at $16.89. The stock’s lowest point was $16.88 before it closed at $16.69. The market performance of BioXcel Therapeutics Inc. has been somewhat stable. Web1 day ago · Anika Therapeutics, Inc. as part of the agreement, the Company appointed Gary Fischetti as a Class III director. Fischetti will join two existing board members on a newly formed Capital Allocation Committee of the Board, which will make recommendations to the Board and support management's review of the Company's capital allocation.
WebView the latest Morphic Holding Inc. (MORF) stock price, news, historical charts, analyst ratings and financial information from WSJ. WebWALTHAM, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin …
WebJun 26, 2024 · WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 26, 2024-- Morphic Holding, Inc. (“ Morphic ”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price to the public of $15.00 per … refresh table syntaxWebMar 1, 2024 · WALTHAM, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral... refresh tears preservativesWebMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical ... refresh tabsWebMar 31, 2024 · Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is … refresh tears preservative free in a bottleWebMorphic Therapeutic is leading the development of a new generation of oral integrin drugs. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders and immuno-oncology. Morphic was created in 2015 with support from Leukon Investment, Polaris … refresh taskbarWebApr 9, 2024 · The last twelve months weren't great for Morphic Holding shares, which performed worse than the market, costing holders 16%. The market shed around 9.2%, no doubt weighing on the stock price. Fortunately the longer term story is brighter, with total returns averaging about 31% per year over three years. refresh table without reloading pageWebAs of March 2024 Morphic Therapeutic's TTM earnings are -$63.4 M. companies: 7,317 total market cap: $83.626 T. Global ranking; Ranking by countries. America ... The … refresh tears precio